{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T18:20:37Z","timestamp":1782498037400,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.clbc.2022.08.007","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T12:07:28Z","timestamp":1661170048000},"page":"e881-e891","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Randomized Controlled Phase 2 Study of Neoadjuvant Eribulin Versus Paclitaxel in Women with Operable Breast Cancer: The JONIE-3 Study"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0135-5001","authenticated-orcid":false,"given":"Kazutaka","family":"Narui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daishu","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshie","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Horiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Miyashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimito","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimitsu","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Akazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3450-4533","authenticated-orcid":false,"given":"Takashi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2022.08.007_bib0001","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2022.08.007_bib0002","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2022.08.007_bib0003","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s12282-020-01139-3","article-title":"Annual report of the Japanese Breast Cancer Registry for 2017","volume":"27","author":"Hayashi","year":"2020","journal-title":"Breast Cancer"},{"key":"10.1016\/j.clbc.2022.08.007_bib0004","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.1200\/JOP.2012.000863","article-title":"Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer","volume":"9","author":"Speck","year":"2013","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.clbc.2022.08.007_bib0005","first-page":"2261","article-title":"Chemotherapy-induced peripheral neuropathy and its association with quality of life: A systematic review","volume":"22","author":"Mols","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clbc.2022.08.007_bib0006","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.clbc.2022.08.007_bib0007","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1158\/1078-0432.CCR-14-3252","article-title":"Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent","volume":"21","author":"Dybdal-Hargreaves","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2022.08.007_bib0008","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/bjc.2016.122","article-title":"In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab","volume":"114","author":"Ueda","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2022.08.007_bib0009","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/bjc.2014.80","article-title":"Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states","volume":"110","author":"Yoshida","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2022.08.007_bib0010","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomized study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2022.08.007_bib0011","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s12282-018-0919-8","article-title":"Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study","volume":"26","author":"Tsurutani","year":"2019","journal-title":"Breast Cancer"},{"key":"10.1016\/j.clbc.2022.08.007_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220644","article-title":"Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study","volume":"14","author":"Di Cosimo","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.clbc.2022.08.007_bib0013","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10549-021-06184-w","article-title":"Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial","volume":"188","author":"Masuda","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2022.08.007_bib0014","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10549-015-3466-4","article-title":"Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9","volume":"152","author":"Abraham","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2022.08.007_bib0015","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1002\/onco.13581","article-title":"A randomized phase II study of sequential eribulin versus paclitaxel followed by FAC\/FEC as neoadjuvant therapy in patients with operable HER2-negative breast cancer","volume":"26","author":"Lim","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2022.08.007_bib0016","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2022.08.007_bib0017","series-title":"National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (Japanese Clinical Oncology Group edition)","year":"2022"},{"key":"10.1016\/j.clbc.2022.08.007_bib0018","first-page":"1483","article-title":"Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02","volume":"17","author":"Shimozuma","year":"2009","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clbc.2022.08.007_bib0019","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2022.08.007_bib0020","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1200\/JCO.2003.12.005","article-title":"The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27","volume":"21","author":"Bear","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2022.08.007_bib0021","article-title":"A randomized phase II neoadjuvant (NACT) study of sequential eribulin followed by FAC\/FEC-regimen compared to sequential paclitaxel followed by FAC\/FEC-regimen in patients (pts) with operable breast cancer not overexpressing HER-2","volume":"76","author":"Lim","year":"2016","journal-title":"Cancer Research"},{"key":"10.1016\/j.clbc.2022.08.007_bib0022","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1111\/bph.15086","article-title":"Taxane-induced neurotoxicity: Pathophysiology and therapeutic perspectives","volume":"177","author":"da Costa","year":"2020","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clbc.2022.08.007_bib0023","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.critrevonc.2015.04.011","article-title":"Taxane induced neuropathy in patients affected by breast cancer: Literature review","volume":"96","author":"De Iuliis","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clbc.2022.08.007_bib0024","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s10549-017-4437-8","article-title":"Long-term peripheral neuropathy symptoms in breast cancer survivors","volume":"166","author":"Mustafa Ali","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2022.08.007_bib0025","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00280-017-3314-9","article-title":"Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese","volume":"79","author":"Tanabe","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clbc.2022.08.007_bib0026","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10549-015-3466-4","article-title":"Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9","volume":"152","author":"Abraham","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2022.08.007_bib0027","article-title":"Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomized clinical trials of early stage breast cancer: systematic review and meta-analysis","volume":"375","author":"Conforti","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.clbc.2022.08.007_bib0028","first-page":"2929","article-title":"Eribulin promotes antitumor immune responses in patients with locally advanced or metastatic breast cancer","volume":"38","author":"Goto","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clbc.2022.08.007_bib0029","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10549-021-06417-y","article-title":"Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)","volume":"193","author":"Geyer","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2022.08.007_bib0030","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-20-4726","article-title":"Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib\/II Study","volume":"27","author":"Tolaney","year":"2021","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820922001847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820922001847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:25:07Z","timestamp":1761513907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820922001847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1526820922001847"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2022.08.007","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomized Controlled Phase 2 Study of Neoadjuvant Eribulin Versus Paclitaxel in Women with Operable Breast Cancer: The JONIE-3 Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2022.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}